Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

An Forbidden Facts Over Dasatinib Exposed By A Professional

1). This correlation was maintained on multivariate analysis after adjusting for age, site of metastasis, and number of metastases (Table 4). In this study, we observed a trend toward improved survival in patients presenting with stage IV breast cancer who underwent surgical resection of the primary tumor. This observation is in keeping with the remarkably consistent findings of other retrospective studies evaluating the role of surgery in the treatment of patients with stage IV disease (Table 5),3-11 and similar outcomes also have been observed in patients receiving radiotherapy for local control in the breast.14 As in prior studies, patients selected for surgery in our cohort represented a somewhat better prognostic group: they tended to have smaller primary tumors and less metastatic disease, and were less likely to have HER-2/neu amplification. However, we found that the survival benefit of surgery was present not only in the group of patients Afatinib with the more favorable hormone receptor?positive status, but also in patients with HER-2/neu?amplified disease when targeted systemic therapy was used. Although a trend toward improved survival after surgical resection of the primary tumor was observed in our overall study cohort, on exploratory analyses this effect was limited to patients with ER/PR positive or HER-2/neu?amplified cancers; patients with triple?negative disease did not experience any differential improvement in survival. To the best of our knowledge, the current study is the first Dasatinib to recognize that the molecular subtype of the primary tumor influences the outcomes of patients with stage IV disease who undergo surgical resection of the primary tumor. However, other recent studies have suggested that the molecular subtype of the primary tumor has a significant influence on outcome Src inhibitor after local treatment, including the likelihood of local disease recurrence after breast conservation or mastectomy, and even overall survival.15-18 In a study by Kyndi et al, the molecular subtypes of the tumors in a subset of patients randomized as part of the Danish Breast Cancer Cooperative Group trials evaluating postmastectomy radiotherapy were reviewed.16 Overall survival in this trial was found to be improved with postmastectomy radiotherapy; however, on subset analyses, this effect was found to be limited to patients who were ER/PR positive and HER-2/neu negative who received tamoxifen. The impact of radiotherapy on locoregional control also was found to be greatest in these subgroups. Similarly, Nguyen et al reported that the molecular subtype impacted the likelihood of local and distant disease recurrence after breast-conserving therapy.17 Patients with ER/PR negative tumors, regardless of HER-2/neu amplification status, were found to have the highest likelihood of disease recurrence, whereas patients with ER/PR positive tumors who received tamoxifen had a 5-year risk of local disease recurrence of <2%.</div>
Sign In or Register to comment.